A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

To be part of this study, you would need to be an adult, aged 18 or older, and have been diagnosed with type 2 diabetes for at least three months. Importantly, your diabetes should not be fully controlled by your current lifestyle or medications, meaning your blood sugar levels (measured by an HbA1c test) should be between 7% and 10.5%. You also need to have a body mass index (BMI) of 23 or higher, and your weight should have been stable for at least 90 days before checking if you can join.

There are certain reasons why someone might not be able to join. For example, if you have type 1 diabetes or a different kind of diabetes, or if you've had severe low blood sugar episodes recently. Also, if you've had certain serious health problems like severe heart failure, pancreatitis, or a history of specific cancers like medullary thyroid cancer, this study might not be suitable for you.

If you join this study, you'll be randomly assigned to one of several treatment groups. This typically means you might receive Elecoglipron, Dapagliflozin, both medicines together, or a placebo (an inactive dummy drug). You'll take the study medication as instructed, and you'll have regular visits to the clinic over a period of time. These visits will involve various health checks, such as blood tests to measure your blood sugar levels (like HbA1c), weight measurements, and checks of your blood pressure and general health. You'll also be asked about any side effects you might experience. The total length of the study for each participant will be explained by the study team, but it will involve consistent follow-up to monitor your health and how you respond to the treatment.